FindTrial
Sign In

The use of Progentix TCP (beta-tricalciumphosphate) as a bone substitute in defects originated from curettage of benign bone tumors

The use of Progentix TCP (beta-tricalciumphosphate) as a bone substitute in defects originated from curettage of benign bone tumors - Progentix TCP as bone substitute after curettage of benign bone tumors

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON31641
Enrollment
10
Registered
2009-06-16
Start date
2008-12-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign bonetumors bonecysts

Interventions

Following curettage of the benign bone tumor the defect will be filled with Progentix TCP. So, a surgical intervention will take place.

Sponsors

Medisch Spectrum Twente
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: benign bonetumors to be treated with curettage

Exclusion criteria

Exclusion criteria: Use of Progentix TCP synthetic cancellous bone void filler is CONTRAINDICATED in the presence of one or more of the following clinical situations: Malignant bonetumors, In case of severe metabolic or systemic bone disorders that affect bone or wound healing, In case of acute and chronic infections in the operated area (soft tissue infections; inflamed, bacterial bone diseases; osteomyelitis), In case of treatment with pharmaceuticals interfering with the calcium metabolism.

Design outcomes

Primary

MeasureTime frame
After 6 weeks, 3 months, 6 months, 1 year and 2 years, the amount of bone formed by "creeping substitution" in the bone defect will be assessed by means of X-rays.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)